The National Program for the Improvement of Management of Fetal Congenital Heart Disease in China
Improvement on Prenatal Screening and Treatment Capabilities for Congenital Heart Disease With a Comprehensive Diagnosis and Treatment Program Incorporating New Technologies Based on Multi-center Collaboration in China
1 other identifier
observational
9,000
0 countries
N/A
Brief Summary
To investigate and evaluate the capacity of prenatal screening, diagnosis and counseling of congenital heart disease in medical institutions in China, in order to understand the current status and existing problems of prenatal prevention and treatment capacity of congenital heart disease in China, and to obtain corresponding baseline data, so as to provide scientific basis for further improving prenatal screening and diagnosis policies in China.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jul 2023
Typical duration for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2023
CompletedFirst Submitted
Initial submission to the registry
July 2, 2023
CompletedFirst Posted
Study publicly available on registry
July 11, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2026
ExpectedJuly 11, 2023
July 1, 2023
2 months
July 2, 2023
July 2, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (4)
The integrity rate of the multi-view acquisition
The integrity rate of the multi-view acquisition
From June 2023 to Oct 2023
Negative coincidence rate congenital heart disease screening
Negative coincidence rate congenital heart disease screening
From June 2023 to Oct 2023
Positive coincidence rate of congenital heart disease screening
Positive coincidence rate of congenital heart disease screening
From June 2023 to Oct 2023
The coincidence rate of multidisciplinary consultation
The coincidence rate of multidisciplinary consultation
From June 2023 to Oct 2023
Study Arms (11)
Liaoning Provincial Maternal and Child Health Hospital
Liaoning Provincial Maternal and Child Health Hospital
Shenyang Maternal and Infant Hospital
Shenyang Maternal and Infant Hospital
Guangdong Women and Children's Hospital
Guangdong Women and Children's Hospital
Guangzhou Women and Children's Medical Center
Guangzhou Women and Children's Medical Center
Guangdong Provincial People's Hospital
Guangdong Provincial People's Hospital
Shandong Maternal and Child Health Hospital
Shandong Maternal and Child Health Hospital
Fujian Provincial Maternal and Child Health Hospital
Fujian Provincial Maternal and Child Health Hospital
Maternal and Child Health Hospital of Hubei Province
Maternal and Child Health Hospital of Hubei Province
Anhui Provincial Maternal and Child Health Hospital
Anhui Provincial Maternal and Child Health Hospital
Peking University First Hospital, Ningxia Women and Children's Hospital
Peking University First Hospital, Ningxia Women and Children's Hospital
Sichuan Maternal and Child Health Hospital
Sichuan Maternal and Child Health Hospital
Interventions
To investigate and evaluate the capacity of prenatal screening, diagnosis and counseling for fetal heart disease based on medical institutions; Improving capacity for prenatal screening, diagnosis and counselling through integrated products embedded with new technologies.
Eligibility Criteria
Pregnant women and physicians performing prenatal screening and diagnosis
You may qualify if:
- All pregnant women and fetuses who underwent prenatal ultrasound examination in the above hospitals were enrolled
You may not qualify if:
- Pregnant women not willing to cooperate
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Yihua He, MD
Beijing Anzhen Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- CROSS SECTIONAL
- Target Duration
- 2 Years
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Director of the Center for Maternal-Fetal Medicine of Fetal Heart Disease
Study Record Dates
First Submitted
July 2, 2023
First Posted
July 11, 2023
Study Start
July 1, 2023
Primary Completion
September 1, 2023
Study Completion (Estimated)
June 1, 2026
Last Updated
July 11, 2023
Record last verified: 2023-07